7Maher AR, Theodore G. Summary of the comparative effectiven- ess review on off-label use of atypical antipsychotics [J]. J Manag Care Pharm, 2012, 18 ( 5 Suppl B ) : S1-20.
8Dal Pan GJ. Monitoring the safety of medicines used off-label [J]. ClinPharmacolTher, 2012, 91 (5) : 787-795.
9Ruble J. Off-label prescribing of medications for pain: maintai- ning optimal care at an intersection of law, public policy, and ethics[J]. J Pain Palliat Care Pharmacother, 2012, 26 (2) : 146-152.
10Meadows WA, Hollowell BD. Off-label ' drug use: an FDA re- gulatory term, not a negative implication of its medical use [J]. Int JlmpotRes, 2008, 20 (2) : 135-144.
4International Conference on Harmonisation; guidance on Ell clinical investigation of medicinal products in the pediatric population; availability. Notice. Federal Register, 2000, 78493-4.
5Crombie I. The pocket guide to critical appraisal London: BMJ Publishing Group; 1996.
6Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics, 1977, 33(1): 159-174.
7Van den Berg H, Tak N. Licensing and labeling of drugs in a pediatric oncology ward. Br J Clin Pharmacol, 2011, 72(3): 474-48l.
8't long GW, van der Linden PD, Bakker EM, et al. Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands. Eur J Clin Pharmacol, 2002, 58(4): 293-297.
9't long GW, Vulto AG, de Hoog M, et al. A survey of the use of offlabel and unlicensed drugs in a Dutch children's hospital. Pediatrics, 2001,108(5): 1089-1093.
10Dessl A, Salemi C, Fanos V, et al. Drug treatments in a neonatal setting:focus on the off-label use in the first month of life. Pharm World Sci, 2010, 32(2): 120-124.
